

ASTRAZENECA PLC  
Form 6-K  
December 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of December 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1. Block listing Interim Review dated 01st December 2016

1 December 2016 16:00

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 1 DECEMBER 2016

Name of applicant: ASTRAZENECA PLC

Name of scheme: ASTRAZENECA SHARE OPTION PLAN;  
ASTRAZENECA SAVINGS-RELATED  
SHARE OPTION PLAN; ASTRAZENECA  
ALL-EMPLOYEE SHARE PLAN;  
ASTRAZENECA PLC 2012  
SAVINGS-RELATED SHARE OPTION  
SCHEME

Period of return: From: 31 MAY 2016 To: 30 NOVEMBER 2016

Balance of unallotted  
securities under  
scheme(s) from previous  
return: 4,065,743

Plus: The amount by  
which the block  
scheme(s) has been  
increased since the date 0  
of the last return (if any  
increase has been  
applied for):

Less: Number of  
securities issued/allotted  
under scheme(s) during 478,408  
period (see LR3.5.7G):

Equals: Balance under  
scheme(s) not yet  
issued/allotted at end of 3,587,335  
period:

Name of contact: MARTIN BENNETT

Telephone number of contact: 07825 530066

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas -

## Edgar Filing: ASTRAZENECA PLC - Form 6-K

Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

### Media Enquiries

Neil Burrows	UK/Global	+44 203 749 5637
Vanessa Rhodes	UK/Global	+44 203 749 5736
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677

### Investor Relations

Thomas Kudsk Larsen		+44 203 749 5712
Craig Marks	Finance, Fixed Income, M&A	+44 7881 615 764
Henry Wheeler	Oncology	+44 203 749 5797
Mitchell Chan	Oncology	+1 240 477 3771
Lindsey Trickett	Cardiovascular & Metabolic Diseases	+1 240 543 7970
Nick Stone	Respiratory	+44 203 749 5716
Christer Gruvris	Autoimmunity, neuroscience & infection	+44 203 749 5711
US toll free		+1 866 381 7277

Adrian Kemp  
Company Secretary, AstraZeneca PLC  
-ENDS-

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Date: 01 December 2016 By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary